Nesline, Mary K. http://orcid.org/0000-0003-0523-4597
Subbiah, Vivek
Previs, Rebecca A.
Strickland, Kyle C.
Ko, Heidi
DePietro, Paul
Biorn, Michael D.
Cooper, Maureen
Wu, Nini
Conroy, Jeffrey
Pabla, Sarabjot
Zhang, Shengle
Wallen, Zachary D.
Sathyan, Pratheesh
Saini, Kamal
Eisenberg, Marcia
Caveney, Brian
Severson, Eric A.
Ramkissoon, Shakti
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 29 December 2023
Accepted: 29 February 2024
First Online: 19 March 2024
Declarations
:
: Mary K. Nesline, Rebecca A. Previs, Kyle C. Strickland, Heidi Ko, Paul DePietro, Michael D. Biorn, Maureen Cooper, Jeffrey Conroy, Sarabjot Pabla, Shengle Zhang, Zachary Wallen, Marcia Eisenberg, Brian Caveney, Eric A. Severson, and Shakti Ramkissoon are employees of Labcorp and declare the following relationships: stock ownership from Labcorp. Vivek Subbiah has had a consulting or advisory role with MedImmune, Helsinn Therapeutics, Relay Therapeutics, Pfizer, Loxo/Lilly, Research Funding from Novartis (Inst), GlaxoSmithKline (Inst), NanCarrier (Inst), Northwest Biotherapeutics (Inst), Genentech/Roche (Inst), Berg Pharma (Inst), Bayer (Inst), Incyte (Inst), Fujifilm (Inst), PharmaMar (Inst), D3 Oncology Solutions (Inst), Pfizer (Inst), Amgen (Inst), AbbVie (Inst), Multivir (Inst), Blueprint Medicines (Inst), Loxo (Inst), Vegenics (Inst), Takeda (Inst), Alfasigma (Inst), Agensys (Inst), Idera (Inst), Boston Biomedical (Inst), Inhibrx (Inst), Exelixis (Inst), Amgen (Inst), Turningpoint Therapeutics (Inst), Relay Therapeutics (Inst). Nini Wu declares that she has no competing interests. Pratheesh Sathyan is an employee of Illumina and declares the following relationships: stock ownership from Illumina. Kamal Saini is an employee of Fortrea and declares the following relationship: stock ownership from Fortrea. Kamal Saini is an Editorial Board member of <i>Oncology and Therapy</i>. Kamal Saini was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions.
: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board (or Ethics Committee) of the Western Institutional Review Board (IRB) Copernicus Group (WCG protocol # 1340120), approved 9/2/2022. The WCG IRB determined that this study met requirements for a waiver of informed consent under 45 CFR 46 116(f) (2018 Requirements) and 45 CFR 46.116(d) (Pre-2018 Requirements]).